Add to ORKGSafety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy Brazilian infant
Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and near...
BACKGROUND: A phase III, double-blind, randomized, controlled trial was conducted in Hong Kong to ...
We evaluated safety and immunogenicity of two orally administered human rotavirus vaccine candidates...
Objective: To determine the safety, immunogenicity and efficacy of two doses of rotavirus vaccine in...
Este estudo foi patrocinado pelo laboratório GlaxoSmithKline Biologicals, Rixensart, Bélgica, e rece...
In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the ...
Background Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of...
This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral li...
Aim: This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses ...
Glaxo SmithKline Biologicals. Rixensart, Belgium.University of Tampere. Medical School. Tampere, Fin...
IEC, SVS, GlaxoSmithKline BiologicalsMinistério da Saúde. Secretaria de Vigilância em Saúde. Institu...
Rotavirus is the most common cause of severe gastroenteritis in children younger than 3 years of age...
Artículo de publicación ISIBACKGROUND: The safety and efficacy of an attenuated G1P[8] human rota...
Rotavirus is a major cause of acute gastroenteritis worldwide and infects almost all children in the...
Ministerio de Salud. Universidad Central de Venezuela. Instituto de Biomedicina. Caracas, VE.Unive...
Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and near...
BACKGROUND: A phase III, double-blind, randomized, controlled trial was conducted in Hong Kong to ...
We evaluated safety and immunogenicity of two orally administered human rotavirus vaccine candidates...
Objective: To determine the safety, immunogenicity and efficacy of two doses of rotavirus vaccine in...
Este estudo foi patrocinado pelo laboratório GlaxoSmithKline Biologicals, Rixensart, Bélgica, e rece...
In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the ...
Background Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of...
This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral li...
Aim: This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses ...
Glaxo SmithKline Biologicals. Rixensart, Belgium.University of Tampere. Medical School. Tampere, Fin...
IEC, SVS, GlaxoSmithKline BiologicalsMinistério da Saúde. Secretaria de Vigilância em Saúde. Institu...
Rotavirus is the most common cause of severe gastroenteritis in children younger than 3 years of age...
Artículo de publicación ISIBACKGROUND: The safety and efficacy of an attenuated G1P[8] human rota...
Rotavirus is a major cause of acute gastroenteritis worldwide and infects almost all children in the...
Ministerio de Salud. Universidad Central de Venezuela. Instituto de Biomedicina. Caracas, VE.Unive...
Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and near...
BACKGROUND: A phase III, double-blind, randomized, controlled trial was conducted in Hong Kong to ...
We evaluated safety and immunogenicity of two orally administered human rotavirus vaccine candidates...